Heart:中重度瓣膜疾病孕妇的预后研究

2020-03-23 MedSci原创 MedSci原创

本荟萃分析的目的旨在评估来自中高等发展国家的中重度先天性心脏瓣膜病(VHD)孕妇的孕期/胎儿预后结局。

本荟萃分析的目的旨在评估来自中高等发展国家的中重度先天性心脏瓣膜病(VHD)孕妇的孕期/胎儿预后结局。

本研究的主要终点事件是孕母死亡率,主要胎儿/新生儿终点事件是死产或新生儿死亡。最终共纳入分析了来自12个临床研究中的646名孕妇,重度二尖瓣狭窄(MS)孕妇的死亡率为3%,肺水肿发生率为37%,新发/复发性心律失常发生率为16%,他们的死产、新生儿死亡和早产率分别为4%、2%和18%。中度MS孕妇的死亡率为1%,肺水肿发生率为18%,新发/复发性心律失常发生率为5%,死产和早产率分别是2%和10%。重度主动脉瓣狭窄(AS)孕妇的死亡、肺水肿和新发/复发性心律失常发生率分别是2%、9%和4%,他们的死产、新生儿死亡和早产率分别为2%、3%和14%,中度AS孕妇未出现死亡病例,而肺水肿、新发/复发性心律失常和早产率分别是8%、2%和13%。

研究结果显示,中重度AS和MS患者发生不良孕期和胎儿事件的风险明显增高,她们应该接受有经验团队提供的怀孕前咨询和怀孕护理。

原始出处:

Robin A et al.Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis.Heart.2020 Mar.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=380955, encodeId=16c5380955f1, content=加油,你们是最棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ea82329997, createdName=1226a71am04(暂无昵称), createdTime=Wed Mar 25 13:55:50 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357448, encodeId=8f45135e448a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563263, encodeId=0c431563263fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583659, encodeId=b6861583659a8, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
    2020-03-25 1226a71am04(暂无昵称)

    加油,你们是最棒的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=380955, encodeId=16c5380955f1, content=加油,你们是最棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ea82329997, createdName=1226a71am04(暂无昵称), createdTime=Wed Mar 25 13:55:50 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357448, encodeId=8f45135e448a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563263, encodeId=0c431563263fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583659, encodeId=b6861583659a8, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
    2020-03-25 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=380955, encodeId=16c5380955f1, content=加油,你们是最棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ea82329997, createdName=1226a71am04(暂无昵称), createdTime=Wed Mar 25 13:55:50 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357448, encodeId=8f45135e448a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563263, encodeId=0c431563263fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583659, encodeId=b6861583659a8, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
    2020-03-25 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=380955, encodeId=16c5380955f1, content=加油,你们是最棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ea82329997, createdName=1226a71am04(暂无昵称), createdTime=Wed Mar 25 13:55:50 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357448, encodeId=8f45135e448a2, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563263, encodeId=0c431563263fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583659, encodeId=b6861583659a8, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Wed Mar 25 00:25:36 CST 2020, time=2020-03-25, status=1, ipAttribution=)]

相关资讯

JACC:口服抗凝药对晚期肾疾病伴房颤患者预后的影响

在晚期肾疾病(ESRD)患者中房颤较常见,口服抗凝药对ESRD患者的影响尚不清楚。

AP&T:非酒精性脂肪肝患者晚期肝纤维化与心血管疾病相关

非酒精性脂肪肝疾病(NAFLD)与心血管疾病的风险增加相关是明确的。但是,尚不清楚哪些NAFLD患者罹患心血管疾病的风险最高。

Eur Heart J:新冠病毒对心血管或有长期影响

3月18日,四川大学华西医院心内科陈茂教授等联合英国学者,在《欧洲心脏病学杂志》上在线发表观点文章指出,新冠病毒感染不仅可导致急性心血管损伤,对患者的心血管系统可能还有长期影响。

JACC:造影剂相关急性肾损伤会增加患者不良预后风险

造影剂相关急性肾损伤(CA-AKI)会增加一系列不良预后的风险,本研究旨在探讨CA-AKI发生后严重不良结局的相对风险和发生率,并探讨CA-AKI是否介导了血管造影前估计的肾小球滤过率与不良结局的关系

盘点:JACC3月第四期研究一览

1.二甲双胍可以减少心脏移植糖尿病患者的脂质沉积

JACC:多种新生物标志物可预测心衰伴保留型射血分数患者的预后

心衰伴保留型射血分数(HFpEF)尚需要更好的风险分层策略,本研究的目的是评估靶向血浆多标记方法在增强HFpEF表型特征和风险预测中的价值。